zum Inhalt springen

Clinical Trials

Foto: Axel Hamprecht

Current Clinical Trials


ClinicalTrials.gov Identifier: NCT03059992

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Sponsor: Scynexis, USA

EU Sponsor Representative: University of Cologne

SCY-078, prepared by chemical modification of enfumafungin, is the lead clinical candidate identified from this platform technology and is being developed as a new intravenous (IV) and oral agent for the treatment of several fungal infections. SCY-078 is an inhibitor of fungal 1,3 – β -glucan and synthesis and shows antifungal activity against a wide range of clinically important fungi, including those that are resistant to azole drugs such as fluconazole.

Link: www.clinicaltrials.gov/ct2/show/NCT03059992